Inhibiting soluble epoxide hydrolase to elevate EET levels shows promise as a therapeutic strategy, while Aβ-induced reductions in CYP epoxygenase activity further exacerbate AD pathology [168,280]. The gene discussed is EPHX2; the disease is Alzheimer disease.